The Trump administration is considering reducing from 12 years to 10 the intellectual property protection period for biologic drugs as a way to gain Democrats' support for a new trade deal with Mexico and Canada, according to people with knowledge of the matter.
The latest figures from the CMS show that nearly 2.4 million people selected Affordable Care Act plans through the federal exchange in the first four weeks of open enrollment this year, down about 2% from the same period last year. The number of people who chose ACA plans in the fourth week reached 703,556, compared with 500,437 the year before, helping narrow the year-over-year gap in enrollment.
Off-the-shelf gene therapies are now considered the next big thing in treatments for leukemias and lymphomas due to the speed with which they can be produced compared with chimeric antigen receptor T-cell treatments, which often take two weeks to produce, a period of time that could see the patient it is intended for deteriorate or even die. One example of such a treatment discussed at the annual meeting of the American Society of Hematology was Fate Therapeutics' off-the-shelf CAR NK cell therapy, the first-of-its-kind treatment that targets multiple antigens.
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 270 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.
Contact PCMA Charles Cote
Vice President, Strategic Communications